Activity and safety of temozolomide in advanced adrenocortical carcinoma patients

in European Journal of Endocrinology

Correspondence should be addressed to A Berruti; Email: alfredo.berruti@gmail.com*(D Cosentini and G Badalamenti contributed equally to this work)
Restricted access

Objective

Temozolomide has shown a significant anti-proliferative activity on adrenocortical cancer (ACC) cells in vitro.

Design

On the basis of these results the drug was prescribed as second/third line in advanced metastatic ACC patients in four referral centers in Italy.

Methods

We retrospectively collected anagraphic, clinical and pathological data of patients with advanced ACC with disease progression to standard chemotherapy plus mitotane who were treated with temozolomide at the dose of 200 mg/m2/die given for 5 consecutive days every 28 days. The primary endpoint was the disease control rate, defined as objective response or disease stabilization after 3 months. Secondary endpoints were overall survival (OS), progression-free survival (PFS) and drug safety.

Results

Twenty-eight patients have been included in the study. Ten patients (35.8%, 95% CI: 17.8–53.8) obtained a disease control from temozolomide treatment. In particular, 1 patient had a complete response, 5 patients a partial response and 4 patients stable disease. Median PFS was 3.5 months and median OS was 7.2 months. Disease response was more frequently observed in patients with methylation of O6-methylguanine-DNA methyltransferase (MGMT) gene. Temozolomide therapy was well tolerated and most toxicities were limited to grade G1–2 according to WHO criteria.

Conclusion

Temozolomide was found active in the management of advanced ACC patients. The disease control rate obtained, however, was short-lived and the prognosis of treated patients was poor.

 

     European Society of Endocrinology

All Time Past Year Past 30 Days
Abstract Views 134 134 134
Full Text Views 18 18 18
PDF Downloads 7 7 7
  • 1

    TerzoloMDaffaraFArditoAZaggiaBBasileVFerrariLBerrutiA. Management of adrenal cancer: a 2013 update. Journal of Endocrinological Investigation 2014 207–217. (https://doi.org/10.1007/s40618-013-0049-2)

    • Search Google Scholar
    • Export Citation
  • 2

    FassnachtMDekkersOMElseTBaudinEBerrutiAde KrijgerRRHaakHRMihaiRAssieGTerzoloM. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology 2018 G1–G46. (https://doi.org/10.1530/EJE-18-0608)

    • Search Google Scholar
    • Export Citation
  • 3

    BerrutiABaudinEGelderblomHHaakHRPorpigliaFFassnachtMPentheroudakisG & ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012 (Supplement 7) vii131–vii138. (https://doi.org/10.1093/annonc/mds231)

    • Search Google Scholar
    • Export Citation
  • 4

    BerrutiAGrisantiSPulzerAClapsMDaffaraFLoliPMannelliMBoscaroMArvatETiberioG Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2017 1358–1365. (https://doi.org/10.1210/jc.2016-2894)

    • Search Google Scholar
    • Export Citation
  • 5

    TerzoloMBaudinAEArditoAKroissMLeboulleuxSDaffaraFPerottiPFeeldersRAdeVriesJHZaggiaB Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. European Journal of Endocrinology 2013 263–270. (https://doi.org/10.1530/EJE-13-0242)

    • Search Google Scholar
    • Export Citation
  • 6

    BerrutiAFassnachtMHaakHElseTBaudinESperonePKroissMKerkhofsTWilliamsARArditoA Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. European Urology 2014 832–838. (https://doi.org/10.1016/j.eururo.2013.11.006)

    • Search Google Scholar
    • Export Citation
  • 7

    BerrutiATerzoloMSperonePPiaADella CasaSGrossDJCarnaghiCCasaliPPorpigliaFManteroF Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer 2005 657–666. (https://doi.org/10.1677/erc.1.01025)

    • Search Google Scholar
    • Export Citation
  • 8

    FassnachtMTerzoloMAllolioBBaudinEHaakHBerrutiAWelinSSchade-BrittingerCLacroixAJarzabB Combination chemotherapy in advanced adrenocortical carcinoma. New England Journal of Medicine 2012 2189–2197. (https://doi.org/10.1056/NEJMoa1200966)

    • Search Google Scholar
    • Export Citation
  • 9

    MegerleFKroissMHahnerSFassnachtM. Advanced adrenocortical carcinoma – what to do when first-line therapy fails? Experimental and Clinical Endocrinology and Diabetes 2019 109–116. (https://doi.org/10.1055/a-0715-1946)

    • Search Google Scholar
    • Export Citation
  • 10

    SperonePFerreroADaffaraFPriolaAZaggiaBVolanteMSantiniDVincenziBBadalamentiGIntriviciC Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocrine-Related Cancer 2010 445–453. (https://doi.org/10.1677/ERC-09-0281)

    • Search Google Scholar
    • Export Citation
  • 11

    HenningJEKDeutschbeinTAltieriBSteinhauerSKircherSSbieraSWildVSchlötelburgWKroissMPerottiP Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. Journal of Clinical Endocrinology and Metabolism 2017 4323–4332. (https://doi.org/10.1210/jc.2017-01624)

    • Search Google Scholar
    • Export Citation
  • 12

    KondaBKirschnerLS. Novel targeted therapies in adrenocortical carcinoma. Current Opinion in Endocrinology, Diabetes, and Obesity 2016 233–241. (https://doi.org/10.1097/MED.0000000000000247)

    • Search Google Scholar
    • Export Citation
  • 13

    Le TourneauCZarwanCHoimesCWongDJBauerSWermkeMGroteHJvon HeydebreckAChinKGulleyJ. Avelumab in patients with metastatic adrenocortical carcinoma (mACC): results from the JAVELIN solid tumor trial. Annals of Oncology 2017 (Supplement 5) mdx371.067. (https://doi.org/10.1186/s40425-018-0424-9)

    • Search Google Scholar
    • Export Citation
  • 14

    CosentiniDGrisantiSDalla VoltaALaganàMFiorentiniCPerottiPSigalaSBerrutiA. Immunotherapy failure in adrenocortical cancer: where next? Endocrine Connections 2018 7 E5–E8. (https://doi.org/10.1530/EC-18-0398)

    • Search Google Scholar
    • Export Citation
  • 15

    MaWLiNAnYZhouCBoCZhangG. Effects of temozolomide and radiotherapy on brain metastatic tumor: a systematic review and meta-analysis. World Neurosurgery 2016 197–205. (https://doi.org/10.1016/j.wneu.2016.04.011)

    • Search Google Scholar
    • Export Citation
  • 16

    KoumarianouAKaltsasGKulkeMHObergKStrosbergJRSpadaFGaldySBarberisMFumagalliCBerrutiA Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects. Neuroendocrinology 2015 274–288. (https://doi.org/10.1159/000430816)

    • Search Google Scholar
    • Export Citation
  • 17

    HadouxJFavierJScoazecJYLeboulleuxSAl GhuzlanACaramellaCDéandreisDBorgetILoriotCChougnetC SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer 2014 2711–2720. (https://doi.org/10.1002/ijc.28913)

    • Search Google Scholar
    • Export Citation
  • 18

    CreemersSGvan KoetsveldPMvan den DungenESKorpershoekEvan KemenadeFJFranssenGJde HerderWWFeeldersRAHoflandLJ. Inhibition of human adrenocortical cancer cell growth by temozolomide in vitro and the role of the MGMT gene. Journal of Clinical Endocrinology and Metabolism 2016 4574–4584. Erratum in: Journal of Clinical Endocrinology and Metabolism 2018 3115–3118. (https://doi.org/10.1210/jc.2016-2768)

    • Search Google Scholar
    • Export Citation
  • 19

    EstellerMGarcia-FoncillasJAndionEGoodmanSNHidalgoOFVanaclochaVBaylinSBHermanJG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New England Journal of Medicine 2000 1350–1354. (https://doi.org/10.1056/NEJM200011093431901) Erratum in: New England Journal of Medicine 2000 1740.

    • Search Google Scholar
    • Export Citation
  • 20

    HegiMEDiserensACGodardSDietrichPYRegliLOstermannSOttenPVan MelleGde TriboletNStuppR. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clinical Cancer Research 2004 1871–1874. (https://doi.org/10.1158/1078-0432.CCR-03-0384)

    • Search Google Scholar
    • Export Citation
  • 21

    HegiMEDiserensACGorliaTHamouMFde TriboletNWellerMKrosJMHainfellnerJAMasonWMarianiL MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine 2005 997–1003. (https://doi.org/10.1056/NEJMoa043331)

    • Search Google Scholar
    • Export Citation
  • 22

    BaudinE & Endocrine Tumor Board of Gustave Roussy. Adrenocortical carcinoma. Endocrinology and Metabolism Clinics of North America 2015 411–434. (https://doi.org/10.1016/j.ecl.2015.03.001) Review Erratum in: Endocrinology and Metabolism Clinics of North America 2015 xix

    • Search Google Scholar
    • Export Citation
  • 23

    FerreroASperonePArditoARossiGDel BuonoSPriolaAMBracardaSTabernaETerzoloMBerrutiA. Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. Journal of Endocrinological Investigation 2013 148–152. (https://doi.org/10.3275/8334)

    • Search Google Scholar
    • Export Citation
  • 24

    KhanTSImamHJuhlinCSkogseidBGröndalSTibblinSWilanderEObergKErikssonB. Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology 2000 1281–1287. (https://doi.org/10.1023/a:1008377915129)

    • Search Google Scholar
    • Export Citation
  • 25

    BaeSHParkMJLeeMMKimTMLeeSHChoSYKimYHKimYJParkCKKimCY. Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. Journal of Korean Medical Science 2014 980–984. (https://doi.org/10.3346/jkms.2014.29.7.980)

    • Search Google Scholar
    • Export Citation
  • 26

    AndersonJRCainKCGelberRD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. Journal of Clinical Oncology 2008 3913–3915. (https://doi.org/10.1200/JCO.2008.16.1000)

    • Search Google Scholar
    • Export Citation